Events & Webinars

BAUN 2022: High-risk nmCRPC - Expert guidance on the management and treatment of patients on androgen receptor inhibitors

Nubeqa Header Image

Description

In this Bayer sponsored symposium, recorded at the British Association of Urological Nurses (BAUN) 2022 annual conference, Ms Louisa Fleure from Guy’s and St Thomas’ NHS Foundation Trust leads a talk about the real-world treatment of nmCRPC, highlighting what is important to the patient and how treatment can be optimised from a multidisciplinary perspective.

Joining her on the expert panel, Dr Vincent Khoo from The Royal Marsden NHS Foundation Trust explores the current treatment options for patients with nmCRPC and provides his expert opinion on identifying and treating eligible patients.

The webinar concludes with an interactive Q&A chaired by Ms Louisa Fleure.

Watch the highlights NOW below.

This webinar was organised and funded by Bayer plc.

Speakers
    • Louisa FleureMs Louisa Fleure

    Louisa Fleure is Urology Consultant Nurse at Guy’s and St Thomas’ NHS Trust, London. She has authored several publications on urology and prostate cancer and presented at regional, national and international meetings on these topics. Louisa has served as trustee for the British Association of Urological Nurses (BAUN) and held the posts of Secretary, Treasurer and Conference Lead. Louisa’s hard work and dedication in the field of advanced prostate cancer has been widely acknowledged and has included: the Lynn Adams Award for leadership and innovation in cancer nursing (2014), runner up in the BJN urology nurse of the year (2015), 2016 BAUN Urology Team of the Year, finalist in oncology quality in Care Awards: prostate cancer survivorship team (2016), and the Nightingale Award (2018).

    Louisa Fleure was awarded The Urology Foundation/BAUN’s ‘Urology Nurse of the Year’ award in November 2019 for her work in providing information and support to men with advanced prostate cancer.

    Louisa is chair of the prostate Special Interest Group for the European Association of Urological Nurses.

    • dr-vincent-khooDr Vincent Khoo

    Vincent Khoo is a Consultant in Clinical Oncology at The Royal Marsden and Honorary Consultant at St George's University Hospitals NHS Foundation Trust as well as Honorary Reader at The Institute of Cancer Research, University of London; Adjunct Professor at Monash University, Melbourne and Associate Professor at University of Melbourne. After qualifying in medicine in 1985, Vincent trained and worked in clinical oncology in the UK, USA and Australia, and leads collaborative research groups in the UK and Australia. Specialising in urological cancers, he is Clinical Lead, Clinical Trials Unit Urology Chelsea (CTUUC), at The Royal Marsden’s Chelsea branch and offers a comprehensive array of therapies, including systemic therapies such as hormonal, targeted therapies and chemotherapy.

Abbreviations: ARI, androgen receptor inhibitor; nmCRPC, non-metastatic castration-resistant prostate cancer.

The evolving nmCRPC treatment landscape
NUBEQA®▼ (darolutamide)
BAUS 2022: Navigating treatment decisions in nmCRPC patients
NUBEQA®▼ (darolutamide)
PP-NUB-GB-1298, February 2024
P3 Prostate Cancer Forum: Series Overview
NUBEQA®▼ (darolutamide) | Xofigo®▼ (radium-223 dichloride)

PP-NUB-GB-1314 | February 2024